✨ Free AI Report
Infant Bacterial Therapeutics AB: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Infant Bacterial Therapeutics AB
Company Research

Infant Bacterial Therapeutics AB: Business Overview, Financials & Competitive Analysis

Infant Bacterial Therapeutics AB is a clinical-stage Swedish pharmaceutical company developing novel therapeutics to prevent serious neonatal diseases in premature infants. The company focuses on probiotic-based drug ...

Analyst-debate audio for Infant Bacterial Therapeutics AB

AskCyborg analysts argue the bull and bear cases for Infant Bacterial Therapeutics AB across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Early-stage biotech with orphan drug potential in niche neonatal indications, offering asymmetric upside if clinical trials...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceutical / Neonatal Therapeutics
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Infant Bacterial Therapeutics AB Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Infant Bacterial Therapeutics AB Overview

Pro stress-test →

Infant Bacterial Therapeutics AB is a clinical-stage Swedish pharmaceutical company developing novel therapeutics to prevent serious neonatal diseases in premature infants. The company focuses on probiotic-based drug candidates targeting conditions like necrotizing enterocolitis (NEC) and gastroschisis, addressing a critical unmet medical need in neonatal care.

Strategic Profile

Pro stress-test →

IBT's lead candidate IBP-9414, a pharma-grade Lactobacillus reuteri probiotic strain, is in advanced clinical development with a pivotal Phase III trial (Connection Study) enrolling over 2,000 premature infants. The company has achieved FDA orphan drug designation for IBP-1016 in gastroschisis, positioning it for accelerated regulatory pathways and market exclusivity in rare pediatric indications.

Competitive Landscape

Pro stress-test →

IBT operates in the specialized neonatal pharmaceutical space with limited direct competition for probiotic-based NEC prevention. Competitors include conventional probiotics and emerging biotechs targeting neonatal conditions, though few have advanced clinical programs. The company's orphan drug designation for gastroschisis provides competitive moat.

Industry Context

Infant Bacterial Therapeutics AB operates in Specialty Pharmaceutical / Neonatal Therapeutics.

Key facts

Founded: 2011 · Headquarters: Stockholm, Sweden · Employees: 10 · Market cap: $97.4M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Infant Bacterial Therapeutics AB.

  • IBP-9414 is in late-stage development addressing NEC, a serious condition affecting premature infants with no proven pharmaceutical preventive currently available
  • FDA orphan drug designation for IBP-1016 provides regulatory incentives and potential market exclusivity for gastroschisis treatment
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Advanced Bio selected for production of drug substance
  • 2024-2025Connection Study ongoing with over 2,000 premature infants enrolled in pivotal Phase III trial
  • +1 moreTrack every material event for Infant Bacterial Therapeutics AB as it happens. Explore monitoring →
Get alerted when Infant Bacterial Therapeutics AB has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ProbioticsNon-pharmaceutical grade probiotics used off-label in neonatal care→Neonatal supportive careStandard management without specific pharmaceutical prevention→

Compare Infant Bacterial Therapeutics AB with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Infant Bacterial Therapeutics AB operates in Specialty Pharmaceutical / Neonatal Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Pharmaceutical / Neonatal Therapeutics research →
NEW · MCP server

Ask your AI assistant about Infant Bacterial Therapeutics AB

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Infant Bacterial Therapeutics AB and its top competitor on Cyborg Score”
“What did Infant Bacterial Therapeutics AB do this quarter?”
“Is Infant Bacterial Therapeutics AB a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Infant Bacterial Therapeutics AB do?+
Infant Bacterial Therapeutics AB is a clinical-stage Swedish pharmaceutical company developing novel therapeutics to prevent serious neonatal diseases in premature infants. The company focuses on probiotic-based drug ...
What is Infant Bacterial Therapeutics AB's Cyborg Score?+
Infant Bacterial Therapeutics AB has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Infant Bacterial Therapeutics AB's main competitors?+
Named competitors include Probiotics, Neonatal supportive care. The full competitive landscape is in the AskCyborg report.
How can I get the full Infant Bacterial Therapeutics AB research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Infant Bacterial Therapeutics AB research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Infant Bacterial Therapeutics AB over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.